We found that high ERBB2 expression was the most prominent feature positively associated with pCR status, which is consistent with recent findings in the phase III KRISTINE neoadjuvant trial comparing T-DM1+P versus docetaxel + carboplatin + trastuzumab + pertuzumab in patients with HER2-positive stage II–III breast cancer (23). Here, ERBB2 is linked to breast cancer.